Go-ahead for Schering AG integration with Bayer

13 November 2006

The way is now clear for Schering AG to be integrated into the Bayer Group. The management of Bayer Schering GmbH (formerly Dritte BV GmbH) has resolved to execute the domination and profit and loss transfer agreement with Schering (Marketletters passim). "This is a milestone along the road to integrating Schering into the Bayer organization," commented Bayer management board chairman Werner Wenning, saying this would be done as quickly as possible.

The domination and profit and loss transfer agreement was entered in the commercial register on October 27. Pursuant to this agreement, Bayer Schering GmbH is offering outside stockholders of Schering cash compensation of 89.36 euros a share. The amount of the offer corresponds to the weighted average price of Schering stock over the three-month period immediately preceding the extraordinary stockholders' meeting of September 13, including the price on that day itself. Further details regarding the cash compensation offer will be announced in the near future. Schering stockholders who choose not to sell their shares will receive an annual guaranteed dividend of 3.62 (net) per share.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight